Biricodar (BioDeep_00000837767)
代谢物信息卡片
化学式: C34H41N3O7 (603.2944356)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC1=CC(=CC(=C1OC)OC)C(=O)C(=O)N2CCCCC2C(=O)OC(CCCC3=CN=CC=C3)CCCC4=CN=CC=C4
InChI: InChI=1S/C34H41N3O7/c1-41-29-20-26(21-30(42-2)32(29)43-3)31(38)33(39)37-19-5-4-16-28(37)34(40)44-27(14-6-10-24-12-8-17-35-22-24)15-7-11-25-13-9-18-36-23-25/h8-9,12-13,17-18,20-23,27-28H,4-7,10-11,14-16,19H2,1-3H3/t28-/m0/s1
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:135847
- PubChem: 3037617
- DrugBank: DB04851
- ChEMBL: CHEMBL350775
- CAS: 159997-94-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- A M Mitchell, M Tom, R H Mortimer. Thyroid hormone export from cells: contribution of P-glycoprotein.
The Journal of endocrinology.
2005 Apr; 185(1):93-8. doi:
10.1677/joe.1.06096. [PMID: 15817830] - Steve Mullin, Nagraj Mani, Trudy H Grossman. Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853).
Antimicrobial agents and chemotherapy.
2004 Nov; 48(11):4171-6. doi:
10.1128/aac.48.11.4171-4176.2004. [PMID: 15504837] - Randall P Rago, Albert Einstein, Richard Lush, Tomasz M Beer, Yoo-Joung Ko, W David Henner, Glenn Bubley, Elizabeth A Merica, Varun Garg, Ene Ette, Matthew W Harding, William S Dalton. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Cancer chemotherapy and pharmacology.
2003 Apr; 51(4):297-305. doi:
10.1007/s00280-003-0573-4. [PMID: 12721757] - Vivien H C Bramwell, Donald Morris, D Scott Ernst, Ingrid Hings, Martin Blackstein, Peter M Venner, Ene I Ette, Matthew W Harding, Allison Waxman, George D Demetri. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2002 Feb; 8(2):383-93. doi:
NULL. [PMID: 11839653] - Susan F Bates, Clara Chen, Robert Robey, Min Kang, William D Figg, Tito Fojo. Reversal of multidrug resistance: lessons from clinical oncology.
Novartis Foundation symposium.
2002; 243(?):83-96; discussion 96. doi:
10.1002/0470846356.ch7. [PMID: 11990784] - R A Peck, J Hewett, M W Harding, Y M Wang, P R Chaturvedi, A Bhatnagar, H Ziessman, F Atkins, M J Hawkins. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2001 Jun; 19(12):3130-41. doi:
10.1200/jco.2001.19.12.3130. [PMID: 11408511] - E K Rowinsky, L Smith, Y M Wang, P Chaturvedi, M Villalona, E Campbell, C Aylesworth, S G Eckhardt, L Hammond, M Kraynak, R Drengler, J Stephenson, M W Harding, D D Von Hoff. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
1998 Sep; 16(9):2964-76. doi:
10.1200/jco.1998.16.9.2964. [PMID: 9738565]